Welcome to N4 Pharma
We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Watch our video animation below to see Nuvec® in action:
Nuvec® is a unique, non-viral adjuvant delivery system that has the potential to revolutionise vaccines and cancer treatments. It’s currently in the pre-clinical phase and you can download our whitepaper to read all about its mode of action, plus watch our Nuvec® animation!
Latest news and updates
Investigation of Nuvec particles for effective gene delivery: ELRIG 2021
Our partners at Medicines Discovery Catapult gave a presentation on behalf of N4 Pharma at the European Laboratory Research & Innovation Group’s (ELRIG) UK meeting in Liverpool this week. The full poster, titled ‘Investigation of [...]
New article: Making good vaccines better
Our CEO, Nigel Theobald, is featured in the June issue of The Medicine Maker reviewing the progress made with #covid19vaccines so far. He also looks at how silica nanoparticles like Nuvec® can help to overcome some of [...]
DirectorsTalk interview: N4 Pharma making ‘considerable’ progress
With the release of the Company Report for 2020, N4 Pharma’s CEO, Nigel Theobald, has spoken to Directors Talk about the highlights of last year year. He provides an update on our new refined strategy [...]